{Reference Type}: Journal Article
{Title}: The engineered agonistic anti-CD40 antibody potentiates the antitumor effects of β-glucan by resetting TAMs.
{Author}: Cheng W;Huang Z;Hao Y;Hua H;Zhang B;Li X;Fu F;Yang J;Zheng K;Zhang X;Qi C;
{Journal}: Immunol Lett
{Volume}: 268
{Issue}: 0
{Year}: 2024 Aug 27
{Factor}: 4.23
{DOI}: 10.1016/j.imlet.2024.106882
{Abstract}: Anti-CD40 antibodies (Abs) have been shown to induce antitumor T-cell responses. We reported that the engineered agonistic anti-CD40 Ab (5C11, IgG4 isotype) recognized human CD40 antigen expressed on a human B lymphoblastoid cell line as well as on splenic cells isolated from humanized CD40 mice. Of note, a single high dosage of 5C11 was able to prohibit tumor growth in parallel with an increase in the population of infiltrated CD8+ T cells. Furthermore, the antitumor effects of 5C11 were enhanced in the presence of β-glucan along with an increase in the population of infiltrated CD8+ T cells. In addition, the numbers of CD86+ TAMs and neutrophils were elevated in the combination of 5C11 and β-glucan compared with either 5C11 or β-glucan alone. Furthermore, the abundance of Faecalibaculum, one of the probiotics critical for tumor suppression, was obviously increased in the combination of 5C11 and β-glucan-treated mice. These data reveal a novel mechanism of tumor suppression upon the combination treatment of 5C11 and β-glucan and propose that the combination treatment of agonistic anti-human CD40 antibody 5C11 and β-glucan could be a promising therapeutic strategy for cancer patients.